Literature DB >> 33613692

Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program.

Nikolaj Frost1, Petros Christopoulos2, Diego Kauffmann-Guerrero3, Jan Stratmann4, Richard Riedel5, Monica Schaefer6, Jürgen Alt7, Sylvia Gütz8, Daniel C Christoph9, Eckart Laack10, Martin Faehling11, Richard Fischer12, Klaus Fenchel13, Sebastian Haen14, Lukas Heukamp15, Christian Schulz16, Frank Griesinger17.   

Abstract

INTRODUCTION: We report on the results of the German early access program (EAP) with the third-generation ALK- and ROS1-inhibitor lorlatinib. PATIENTS AND METHODS: Patients with documented treatment failure of all approved ALK/ROS1-specific therapies or with resistance mutations not covered by approved inhibitors or leptomeningeal carcinomatosis were enrolled and analyzed.
RESULTS: In total, 52 patients were included [median age 57 years (range 32-81), 54% female, 62% never smokers, 98% adenocarcinoma]; 71% and 29% were ALK- and ROS1-positive, respectively. G1202R and G2032R resistance mutations prior to treatment with lorlatinib were observed in 10 of 26 evaluable patients (39%), 11 of 39 patients showed TP53 mutations (28%). Thirty-six patients (69%) had active brain metastases (BM) and nine (17%) leptomeningeal carcinomatosis when entering the EAP. Median number of prior specific TKIs was 3 (range 1-4). Median duration of treatment, progression-free survival (PFS), response rate and time to treatment failure were 10.4 months, 8.0 months, 54% and 13.0 months. Calculated 12-, 18- and 24-months survival rates were 65, 54 and 47%, overall survival since primary diagnosis (OS2) reached 79.6 months. TP53 mutations were associated with a substantially reduced PFS (3.7 versus 10.8 month, HR 3.3, p = 0.003) and were also identified as a strong prognostic biomarker (HR for OS2 3.0 p = 0.02). Neither prior treatments with second-generation TKIs nor BM had a significant influence on PFS and OS.
CONCLUSIONS: Our data from real-life practice demonstrate the efficacy of lorlatinib in mostly heavily pretreated patients, providing a clinically meaningful option for patients with resistance mutations not covered by other targeted therapies and those with BM or leptomeningeal carcinomatosis.
© The Author(s), 2021.

Entities:  

Keywords:  ALK; NSCLC; ROS1; TP53; brain metastases; early access program; lorlatinib

Year:  2021        PMID: 33613692      PMCID: PMC7876585          DOI: 10.1177/1758835920980558

Source DB:  PubMed          Journal:  Ther Adv Med Oncol        ISSN: 1758-8340            Impact factor:   8.168


  35 in total

1.  Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.

Authors:  Aaron N Hata; Alice T Shaw; Satoshi Yoda; Jessica J Lin; Michael S Lawrence; Benjamin J Burke; Luc Friboulet; Adam Langenbucher; Leila Dardaei; Kylie Prutisto-Chang; Ibiayi Dagogo-Jack; Sergei Timofeevski; Harper Hubbeling; Justin F Gainor; Lorin A Ferris; Amanda K Riley; Krystina E Kattermann; Daria Timonina; Rebecca S Heist; A John Iafrate; Cyril H Benes; Jochen K Lennerz; Mari Mino-Kenudson; Jeffrey A Engelman; Ted W Johnson
Journal:  Cancer Discov       Date:  2018-04-12       Impact factor: 39.397

2.  ROS1 rearrangements define a unique molecular class of lung cancers.

Authors:  Kristin Bergethon; Alice T Shaw; Sai-Hong Ignatius Ou; Ryohei Katayama; Christine M Lovly; Nerina T McDonald; Pierre P Massion; Christina Siwak-Tapp; Adriana Gonzalez; Rong Fang; Eugene J Mark; Julie M Batten; Haiquan Chen; Keith D Wilner; Eunice L Kwak; Jeffrey W Clark; David P Carbone; Hongbin Ji; Jeffrey A Engelman; Mari Mino-Kenudson; William Pao; A John Iafrate
Journal:  J Clin Oncol       Date:  2012-01-03       Impact factor: 44.544

3.  EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer.

Authors:  Petros Christopoulos; Volker Endris; Farastuk Bozorgmehr; Mei Elsayed; Martina Kirchner; Jonas Ristau; Ivo Buchhalter; Roland Penzel; Felix J Herth; Claus P Heussel; Martin Eichhorn; Thomas Muley; Michael Meister; Jürgen R Fischer; Stefan Rieken; Arne Warth; Helge Bischoff; Peter Schirmacher; Albrecht Stenzinger; Michael Thomas
Journal:  Int J Cancer       Date:  2018-01-24       Impact factor: 7.396

4.  Clinical impact of crizotinib on central nervous system progression in ALK-positive non-small lung cancer.

Authors:  Tatsuya Yoshida; Yuko Oya; Kosuke Tanaka; Junichi Shimizu; Yoshitsugu Horio; Hiroaki Kuroda; Yukinori Sakao; Toyoaki Hida; Yasushi Yatabe
Journal:  Lung Cancer       Date:  2016-04-23       Impact factor: 5.705

5.  Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

Authors:  Alice T Shaw; Beow Y Yeap; Mari Mino-Kenudson; Subba R Digumarthy; Daniel B Costa; Rebecca S Heist; Benjamin Solomon; Hannah Stubbs; Sonal Admane; Ultan McDermott; Jeffrey Settleman; Susumu Kobayashi; Eugene J Mark; Scott J Rodig; Lucian R Chirieac; Eunice L Kwak; Thomas J Lynch; A John Iafrate
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

Review 6.  Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era.

Authors:  J Remon; E Le Rhun; B Besse
Journal:  Cancer Treat Rev       Date:  2016-12-30       Impact factor: 12.111

7.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Authors:  Benjamin J Solomon; Tony Mok; Dong-Wan Kim; Yi-Long Wu; Kazuhiko Nakagawa; Tarek Mekhail; Enriqueta Felip; Federico Cappuzzo; Jolanda Paolini; Tiziana Usari; Shrividya Iyer; Arlene Reisman; Keith D Wilner; Jennifer Tursi; Fiona Blackhall
Journal:  N Engl J Med       Date:  2014-12-04       Impact factor: 91.245

8.  Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.

Authors:  Andrew J Weickhardt; Benjamin Scheier; Joseph Malachy Burke; Gregory Gan; Xian Lu; Paul A Bunn; Dara L Aisner; Laurie E Gaspar; Brian D Kavanagh; Robert C Doebele; D Ross Camidge
Journal:  J Thorac Oncol       Date:  2012-12       Impact factor: 15.609

Review 9.  Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors.

Authors:  Puey Ling Chia; Paul Mitchell; Alexander Dobrovic; Thomas John
Journal:  Clin Epidemiol       Date:  2014-11-20       Impact factor: 4.790

10.  Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.

Authors:  Suresh S Ramalingam; Johan Vansteenkiste; David Planchard; Byoung Chul Cho; Jhanelle E Gray; Yuichiro Ohe; Caicun Zhou; Thanyanan Reungwetwattana; Ying Cheng; Busyamas Chewaskulyong; Riyaz Shah; Manuel Cobo; Ki Hyeong Lee; Parneet Cheema; Marcello Tiseo; Thomas John; Meng-Chih Lin; Fumio Imamura; Takayasu Kurata; Alexander Todd; Rachel Hodge; Matilde Saggese; Yuri Rukazenkov; Jean-Charles Soria
Journal:  N Engl J Med       Date:  2019-11-21       Impact factor: 91.245

View more
  7 in total

Review 1.  Leptomeningeal Metastases: New Opportunities in the Modern Era.

Authors:  Jessica A Wilcox; Min Jun Li; Adrienne A Boire
Journal:  Neurotherapeutics       Date:  2022-07-05       Impact factor: 7.620

2.  Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach.

Authors:  Fabienne Englmeier; Annalen Bleckmann; Wolfgang Brückl; Frank Griesinger; Annette Fleitz; Klaus Nagels
Journal:  J Cancer Res Clin Oncol       Date:  2022-05-09       Impact factor: 4.553

3.  Meningeal "Lazarus Response" to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib.

Authors:  Francesco Facchinetti; Antonin Levy; Samy Ammari; Charles Naltet; Pernelle Lavaud; Mihaela Aldea; Damien Vasseur; David Planchard; Benjamin Besse
Journal:  Cancer Manag Res       Date:  2021-03-26       Impact factor: 3.989

Review 4.  Challenges and Advances in Diagnosis and Treatment of Leptomeningeal Disease (LMD).

Authors:  Sherise D Ferguson; Elena I Fomchenko; Renato A Guerrieri; Isabella C Glitza Oliva
Journal:  Front Oncol       Date:  2022-01-12       Impact factor: 6.244

5.  TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy-EGFR mutated non-small cell lung cancer IV patients treated with osimertinib.

Authors:  Julia Roeper; Petros Christopoulos; Markus Falk; Lukas C Heukamp; Markus Tiemann; Albrecht Stenzinger; Michael Thomas; Frank Griesinger
Journal:  Transl Lung Cancer Res       Date:  2022-01

6.  Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study.

Authors:  N Girard; S Galland-Girodet; V Avrillon; B Besse; M Duruisseaux; J Cadranel; J Otto; A Prevost; B Roch; J Bennouna; K Bouledrak; M Coudurier; T Egenod; R Lamy; C Ricordel; D Moro-Sibilot; L Odier; J Tillon-Strozyk; G Zalcman; P Missy; V Westeel; S Baldacci
Journal:  ESMO Open       Date:  2022-02-26

7.  Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy.

Authors:  Balázs Jóri; Markus Falk; Iris Hövel; Peggy Weist; Markus Tiemann; Lukas C Heukamp; Frank Griesinger
Journal:  Curr Oncol       Date:  2022-09-16       Impact factor: 3.109

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.